WallStSmart
ARMP

Armata Pharmaceuticals Inc

NYSE MKT: ARMP · HEALTHCARE · BIOTECHNOLOGY

$9.87
+3.35% today

Updated 2026-04-30

Market cap
$366.22M
P/E ratio
P/S ratio
74.68x
EPS (TTM)
$-4.80
Dividend yield
52W range
$1 – $15
Volume
0.1M

Armata Pharmaceuticals Inc (ARMP) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-46.1%
Last 4 quarters
Revenue YoY growth
-12.1%
Most recent quarter
EPS YoY growth
-120.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-3.6%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.5%
2025-11-12
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-19$-0.51-169.1%$8.54$8.39-1.8%
2025-11-12$-0.74-48.0%$6.75$6.38-5.5%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.19$-0.51-169.1%$1.08M-12.1%
2025-09-30$-0.50$-0.74-48.0%$1.16M-61.0%
2025-06-30$-0.39$-0.45-15.4%$2.17M
2025-03-31$-0.38$-0.20+48.1%$491000.00-49.2%
2024-12-31$-0.35$-0.23+33.8%$1.24M-19.2%
2024-09-30$-0.28$-0.15+46.4%$2.97M+142.7%
2024-06-30$-0.44$0.25+156.8%
2024-03-31$-0.31$-0.69-122.6%$966000.00+21.4%
2023-12-31$-0.35$-0.55-57.1%$1.53M
2023-09-30$-0.31$-0.75-141.9%$1.23M
2023-06-30$-0.37$-0.10+73.0%$980000.00
2023-03-31$-0.32$-0.40-25.0%$796000.00

Frequently asked questions

Has Armata Pharmaceuticals Inc beaten earnings estimates?
Armata Pharmaceuticals Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -46.1% over the last 4 quarters.
How does ARMP stock react to earnings?
ARMP stock has moved an average of -3.6% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Armata Pharmaceuticals Inc's revenue growth rate?
Armata Pharmaceuticals Inc reported year-over-year revenue growth of -12.1% in its most recent quarter, with EPS growing -120.6% year-over-year.